

# Gilmar Reis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716187/publications.pdf>

Version: 2024-02-01

62  
papers

17,740  
citations

81900

39  
h-index

144013

57  
g-index

67  
all docs

67  
docs citations

67  
times ranked

17000  
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
2	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	27.0	2,261
3	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	27.0	2,211
4	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	13.7	1,625
5	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015, 385, 2067-2076.	13.7	659
6	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	13.7	651
7	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 437.	7.4	581
8	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
9	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	13.7	426
10	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	13.7	425
11	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	13.7	394
12	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
13	Effect of early treatment with flvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. <i>The Lancet Global Health</i> , 2022, 10, e42-e51.	6.3	296
14	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	3.9	218
15	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019, 7, 618-628.	11.4	207
16	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	27.0	205
17	A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2014, 59, 51-61.	5.8	184
18	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180.	13.7	155

#	ARTICLE	IF	CITATIONS
19	Effect of Early Treatment with Ivermectin among Patients with Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 1721-1731.	27.0	142
20	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	139
21	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
22	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	2.8	131
23	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
24	How COVID-19 has fundamentally changed clinical research in global health. <i>The Lancet Global Health</i> , 2021, 9, e711-e720.	6.3	122
25	Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. <i>American Journal of Cardiology</i> , 1995, 75, 707-710.	1.6	113
26	Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. <i>Journal of the American College of Cardiology</i> , 2004, 43, 393-401.	2.8	112
27	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e216468.	5.9	111
28	Risk factors for myocardial infarction in Brazil. <i>American Heart Journal</i> , 2003, 146, 331-338.	2.7	107
29	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
30	Management of acute coronary syndromes in developing countries: ACute Coronary Eventsâ€™a multinational Survey of current management Strategies. <i>American Heart Journal</i> , 2011, 162, 852-859.e22.	2.7	87
31	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	2.0	83
32	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1919.	7.4	72
33	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , 2013, 34, 3117-3127.	2.2	53
34	Cardioversion of Atrial Fibrillation in <sc>ENGAGE AFâ€™TIMI</sc> 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	1.8	53
35	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	2.8	49
36	Cangrelor With and Without Glycoproteinâ€™IIb/IIIa Inhibitors inâ€™Patientsâ€™Undergoing Percutaneousâ€™Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	2.8	47

#	ARTICLE	IF	CITATIONS
37	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. <i>Stroke</i> , 2014, 45, 2372-2378.	2.0	46
38	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	2.2	45
39	Management and 1-year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
40	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
41	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
42	III Diretriz sobre tratamento do infarto agudo do miocárdio. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 83, 1-86.	0.8	24
43	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1364-1366.	1.4	23
44	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	2.7	21
45	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
46	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	8.6	20
47	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	8.6	19
48	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
49	Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100142.	2.6	17
50	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
51	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13
52	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). <i>International Journal of Cardiology</i> , 2013, 168, 2416-2422.	1.7	10
53	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. <i>Gates Open Research</i> , 0, 5, 117.	1.1	9
54	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Evaluating COVID-19 vaccines in the real world. Lancet, The, 2022, 399, 1205-1206.	13.7	7
56	Fluvoxamine for the treatment of COVID-19 – Author's reply. The Lancet Global Health, 2022, 10, e333.	6.3	4
57	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research, 0, 5, 117.	1.1	2
58	Incorporating evidence-based principles in medical training. Sharing experience with McMaster. MedEdPublish, 2018, 7, .	0.3	1
59	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	1.4	1
60	Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. Contemporary Clinical Trials, 2021, 107, 106466.	1.8	0
61	Ecocardiograma sob estresse com dobutamina em pacientes assintomáticos com regurgitação aórtica. Arquivos Brasileiros De Cardiologia, 2009, 93, 53-8.	0.8	0
62	Sharing best practices in applications of evidence-based medicine, problem-based learning and self-directed learning principles in medical training: A McMaster-Brazil collaboration workshop report. MedEdPublish, 2019, 8, .	0.3	0